COMMUNIQUÉS West-GlobeNewswire

Abeona Therapeutics® Announces Option Exercise by Beacon Therapeutics for Novel AAV204 Capsid for Ophthalmology Gene Therapy
01/07/2025
Abeona will receive a license payment and potential development, regulatory, and sales milestones, and royalties CLEVELAND, July 01, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced that [...]
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
01/07/2025
CLEVELAND, July 01, 2025 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO) today announced it has granted equity awards to new non-executive employees who joined the Company. The equity awards were approved in [...]
Bio Usawa Biotechnology and Bioeq AG Partner to Create Widespread Access to Vision-Saving Medicine Across Sub-Saharan Africa
01/07/2025
Landmark partnership will democratize access to critical eye treatment for millions facing preventable blindness from diabetes complications KIGALI, Rwanda and SAN FRANCISCO and ZUG, Switzerland , July 01, 2025 (GLOBE [...]
Jade Biosciences Appoints Brad Dahms as Chief Financial Officer
01/07/2025
SAN FRANCISCO and VANCOUVER, British Columbia, July 01, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”) (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class therapies for autoimmune [...]
Adagene announces up to $25 million strategic investment from Sanofi
01/07/2025
- Sanofi to exercise option on third SAFEbody discovery program and sponsor combination clinical trial with muzastotug - Company expects proceeds to extend cash runway into 2027 SAN DIEGO and SUZHOU, China, July 01, [...]
BioXcel Therapeutics Receives Second Positive Recommendation from Data Safety Monitoring Board (DSMB) to Continue SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or Schizophrenia
01/07/2025
DSMB recommended the continuation of trial as planned Topline data expected in Q3 2025 NEW HAVEN, Conn., July 01, 2025 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing [...]
Breckenridge Distillery Unveils Limited-Edition Collectors Art Series Collaboration with Renowned Artist Miles Toland
01/07/2025
For Its Fifth Annual Collectors Art Series, Breckenridge Distillery Partners with Visionary Artist to Create Label for Its New Calvados Cask Release BRECKENRIDGE, Colo., July 01, 2025 (GLOBE NEWSWIRE) -- Breckenridge [...]
NewGen Subsidiary Secures Strategic UAE Land and Begins Exploration of Potential Real World Asset Tokenization Initiative
01/07/2025
The tokenization initiative would be made in connection with a real estate project with a projected sales revenue exceeding US$400 million BANGKOK, July 01, 2025 (GLOBE NEWSWIRE) -- NewGenIvf Group Limited (NASDAQ: NIVF [...]
Verano to Report Second Quarter 2025 Financial Results on August 7, 2025
01/07/2025
CHICAGO, July 01, 2025 (GLOBE NEWSWIRE) -- Verano Holdings Corp. (Cboe CA: VRNO) (OTCQX: VRNOF) (“Verano” or the “Company”), a leading multi-state cannabis company, today announced that it plans to release financial [...]
Verrica Pharmaceuticals Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical to Launch Global Pivotal Phase 3 Clinical Trial to Study YCANTH® for the Treatment of Common Warts
01/07/2025
– Verrica to receive a $8 million milestone payment for initiation of the global study in July 2025, ahead of previous schedule – – Verrica to receive a $10 million milestone payment from Torii in cash upon the approval [...]
Apellis to Receive up to $300 Million from Royalty Purchase Agreement with Sobi for Ex-U.S. Royalties of Aspaveli® (systemic pegcetacoplan)
01/07/2025
Apellis to receive $275 million upfront and up to $25 million in milestone payments upon EMA approval in C3G and IC-MPGN Non-dilutive financing further strengthens Apellis’ balance sheet Apellis retains full U.S. [...]
EDAP Announces Transition from Foreign Private Issuer to U.S. Domestic Filer Status
01/07/2025
Transition to U.S. reporting status to take effect on January 1, 2026 AUSTIN, Texas, July 1, 2025 - EDAP TMS SA (Nasdaq: EDAP) (“the Company” or “EDAP”), the global leader in robotic energy-based therapies, announced a [...]
atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression
01/07/2025
Study met its primary and all key secondary endpoints, and BPL-003 demonstrated rapid, robust and durable antidepressant effects with a single dose Both 8 mg and 12 mg single doses of BPL-003 showed statistically [...]
Genenta Announces Long-Term Follow-Up Observations in Brain Tumor (GBM) Study with Emerging Survival Signals
01/07/2025
Genitourinary Tumor Study Ongoing with Active Screening and Enrollment MILAN and NEW YORK, July 01, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a pioneer in immuno-oncology, today announced that a total of [...]
AB Science : Résultats de l'Assemblée Générale Mixte du 30 juin 2025
01/07/2025
COMMUNIQUE DE PRESSE RESULTATS DE L’ASSEMBLEE GENERALE MIXTE DU 30 JUIN 2025 Paris, 1 er juillet 2025, 10h15 Les actionnaires de la société AB Science se sont réunis en Assemblée Générale Mixte, le lundi 30 juin 2025 à [...]
Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol)
01/07/2025
REYKJAVIK, Iceland and LONDON, July 01, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and [...]
Alvotech and Advanz Pharma Enter into European Supply and Commercialization Agreement for Biosimilar Candidate to Cimzia® (certolizumab pegol)
01/07/2025
REYKJAVIK, ICELAND and LONDON, UK (July 1, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma [...]
UK MHRA Approval Received for First-In-Human Trial of Rincell-1, a First-In-Class Regenerative Cell Therapy for Sensorineural Hearing Loss
01/07/2025
Rincell-1 addresses a multi $Bn global market opportunity where no disease modifying treatments currently exist Sheffield, July 01, 2025 (GLOBE NEWSWIRE) -- UK MHRA Approval Received for First-In-Human Trial of Rincell- [...]
ONWARD Medical Files 510(k) with US FDA for ARC-EX System Home Use and Submits CE Mark Application
01/07/2025
FDA 510(k) application submitted to allow marketing of the ARC-EX ® System for home use in the United States CE Mark application filed with notified body to enable commercialization of the ARC-EX System in the European [...]

Pages